A Phase 2 clinical trial of ZB021
Latest Information Update: 09 Apr 2026
At a glance
- Drugs ZB 021 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 09 Apr 2026 New trial record
- 27 Mar 2026 According to Zenas BioPharma media release, the company will use the net proceeds from the Convertible Notes Offering and the Equity Offering for funding the ZB021 Phase 1 and Phase 2 clinical development.